212 related articles for article (PubMed ID: 10555887)
1. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
[TBL] [Abstract][Full Text] [Related]
2. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
[TBL] [Abstract][Full Text] [Related]
3. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
4. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
5. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
6. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
Hoekstra M; van de Laar MA; Bernelot Moens HJ; Kruijsen MW; Haagsma CJ
J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
[TBL] [Abstract][Full Text] [Related]
7. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
[TBL] [Abstract][Full Text] [Related]
11. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
Aletaha D; Smolen JS
J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
[TBL] [Abstract][Full Text] [Related]
13. The methotrexate therapeutic response in rheumatoid arthritis.
Ortendahl M; Holmes T; Schettler JD; Fries JF
J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
Ortendahl M; Schettler JD; Fries JF
J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
[TBL] [Abstract][Full Text] [Related]
15. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
Osiri M; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
[TBL] [Abstract][Full Text] [Related]
16. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
Wolfe F; Michaud K; Stephenson B; Doyle J
J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
[TBL] [Abstract][Full Text] [Related]
17. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
19. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Agarwal S; Zaman T; Handa R
Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
[TBL] [Abstract][Full Text] [Related]
20. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]